Various studies suggested a clinical utility of CEA serum assessment in gastric [59], pancreatic [60], non-small-cell lung [61], and breast cancer [62], although the majority of these studies did not improve patient selection by immunohistochemical CEA analysis of the tumor tissue. This evidence concerns the gene CEACAM5 and breast carcinoma.